Inhibitor Therapeutics, Inc. financial data

Symbol
INTI on OTC
Location
Tampa, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1649% % -51%
Debt-to-equity 325% % 340%
Return On Equity -338% % -378%
Return On Assets -80% % -96%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 172,573,545 shares 0.14%
Common Stock, Shares, Outstanding 172,573,545 shares 0.14%
Entity Public Float $6,600,000 USD 106%
Common Stock, Value, Issued $17,257 USD 0.14%
Weighted Average Number of Shares Outstanding, Basic 172,573,545 shares 0.14%
Weighted Average Number of Shares Outstanding, Diluted 172,573,545 shares 0.14%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $1,752,264 USD 13%
General and Administrative Expense $1,843,524 USD -2.6%
Operating Income (Loss) $3,595,788 USD -4.3%
Net Income (Loss) Attributable to Parent $3,426,815 USD -11%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,976,658 USD -53%
Assets, Current $3,064,086 USD -53%
Operating Lease, Right-of-Use Asset $71,081 USD
Assets $3,135,167 USD -51%
Accounts Payable, Current $19,646 USD 1052%
Accrued Liabilities, Current $40,432 USD -5.6%
Liabilities, Current $87,533 USD 96%
Long-term Debt and Lease Obligation $44,181 USD
Liabilities $3,131,714 USD 2.9%
Retained Earnings (Accumulated Deficit) $54,124,229 USD -6.8%
Stockholders' Equity Attributable to Parent $715,637 USD -83%
Liabilities and Equity $3,135,167 USD -51%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,284,969 USD -11%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 172,573,545 shares 0.14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,284,969 USD -11%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,976,658 USD -53%
Deferred Tax Assets, Valuation Allowance $6,293,356 USD 15%
Deferred Tax Assets, Gross $6,293,356 USD 15%
Operating Lease, Liability $71,636 USD
Lessee, Operating Lease, Liability, to be Paid $78,627 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $32,140 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6,991 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $33,104 USD
Deferred Tax Assets, Operating Loss Carryforwards $4,042,984 USD 15%
Lessee, Operating Lease, Liability, to be Paid, Year Four $5,544 USD
Operating Lease, Payments $7,839 USD
Additional Paid in Capital $54,110,425 USD 0.04%